262 related articles for article (PubMed ID: 35203733)
1. Association of
Sid Ahmed MA; Khan FA; Hadi HA; Skariah S; Sultan AA; Salam A; Al Khal AL; Söderquist B; Ibrahim EB; Omrani AS; Jass J
Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203733
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
[TBL] [Abstract][Full Text] [Related]
3. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS
J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587
[TBL] [Abstract][Full Text] [Related]
5. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
[TBL] [Abstract][Full Text] [Related]
6. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of cephalosporin-beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant
Alnimr AM; Alamri AM
J Taibah Univ Med Sci; 2020 Jun; 15(3):203-210. PubMed ID: 32647515
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
Arca-Suárez J; Lasarte-Monterrubio C; Rodiño-Janeiro BK; Cabot G; Vázquez-Ucha JC; Rodríguez-Iglesias M; Galán-Sánchez F; Beceiro A; González-Bello C; Oliver A; Bou G
J Antimicrob Chemother; 2021 Jan; 76(1):91-100. PubMed ID: 33083833
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of
Ahmed MAS; Ibrahim EB; Hamid JM; Daghfal J; Alyazidi MA; Abdelwahab AH; Al-Maslamani MA; Al Khal AL; Abdel Hadi H
Oman Med J; 2022 Sep; 37(5):e422. PubMed ID: 36188876
[TBL] [Abstract][Full Text] [Related]
11. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
Ortiz de la Rosa JM; Nordmann P; Poirel L
J Antimicrob Chemother; 2019 Jul; 74(7):1934-1939. PubMed ID: 31225611
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
Alonso-García I; Vázquez-Ucha JC; Lasarte-Monterrubio C; González-Mayo E; Lada-Salvador P; Vela-Fernández R; Aja-Macaya P; Guijarro-Sánchez P; Rumbo-Feal S; Muíño-Andrade M; Fernández-González A; Martínez-Guitián M; Beceiro A; Rodríguez-Iglesias M; Oliver A; Arca-Suárez J; Galán-Sánchez F; Bou G
J Antimicrob Chemother; 2023 May; 78(5):1195-1200. PubMed ID: 36918743
[TBL] [Abstract][Full Text] [Related]
13. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
[TBL] [Abstract][Full Text] [Related]
14. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP;
Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
16. In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
Int J Antimicrob Agents; 2023 May; 61(5):106772. PubMed ID: 36878411
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
van Duin D; Bonomo RA
Clin Infect Dis; 2016 Jul; 63(2):234-41. PubMed ID: 27098166
[TBL] [Abstract][Full Text] [Related]
19. First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against
Rahimzadeh M; Habibi M; Bouzari S; Asadi Karam MR
Infect Drug Resist; 2020; 13():533-541. PubMed ID: 32110063
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against
Sader HS; Duncan LR; Doyle TB; Castanheira M
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab126. PubMed ID: 34514403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
